FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896588461> ?p ?o ?g. }

• W2896588461 endingPage "153303381880631" @default.
• W2896588461 startingPage "153303381880631" @default.
• W2896588461 abstract "Although stereotactic body radiation therapy is one of the standard treatments for stage I nonsmall cell lung cancer, in the case of central tumors it carries the risk of severe adverse events for serial organs. Accelerated hypofractionated radiotherapy is considered a reasonable alternative to treat central tumors. We have been treating central tumors with accelerated hypofractionated radiotherapy using a 75 Gy/25 fr/5 weeks regimen, and we compared the results with those of stereotactic body radiation therapy using 48 Gy/4 fr/1 week.Patients with central tumors and/or unfit for 1-hour fixation were candidates for accelerated hypofractionated radiotherapy. Based on the proximity to the biologically effective dose at 10 Gy, above accelerated hypofractionated radiotherapy regimen was adopted.From October 2003 to December 2010, 159 patients, who received either accelerated hypofractionated radiotherapy (103 cases) or stereotactic body radiation therapy (56 cases), were included in the analysis. In the accelerated hypofractionated radiotherapy group, 40 (39%) cases were central tumors, whereas all cases were peripheral tumors in the stereotactic body radiation therapy group. Overall 5-year local control and survival rates were 81.9% (95% confidence interval 73.6%-90.1%) and 46.5% (95% confidence interval 36.7%-56.2%), respectively for the accelerated hypofractionated radiotherapy group, and 75.4% (95% confidence interval 63.0%-87.8%) and 44.6% (95% confidence interval 31.6%-57.7%), respectively for the stereotactic body radiation therapy group (n.s.). Among central tumors, ultracentral tumors (21 cases) and the remaining central tumors (19 cases) were similar in both local control and survival. On multivariate analysis, hazard ratios for accelerated hypofractionated radiotherapy versus stereotactic body radiation therapy were <1 for both local control and survival. Pulmonary toxicity was similar in both groups. No serial organ toxicity was observed for central tumors.Accelerated hypofractionated radiotherapy with a 75 Gy/25 fr/5 weeks regimen is promising in that it can obtain similar local control and survival results to stereotactic body radiation therapy, and it can control both central and peripheral tumors without any serial organ toxicities. Based on these results, prospective multicenter trials are worth conducting, especially for ultracentral tumors." @default.
• W2896588461 created "2018-10-26" @default.
• W2896588461 creator A5030364395 @default.
• W2896588461 creator A5036351853 @default.
• W2896588461 creator A5037020713 @default.
• W2896588461 creator A5049066873 @default.
• W2896588461 creator A5064981458 @default.
• W2896588461 creator A5066700160 @default.
• W2896588461 creator A5074236699 @default.
• W2896588461 creator A5081787271 @default.
• W2896588461 creator A5084272595 @default.
• W2896588461 date "2018-01-01" @default.
• W2896588461 modified "2023-09-30" @default.
• W2896588461 title "Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer—A Single Institution Experience With Long-Term Follow-Up" @default.
• W2896588461 cites W1965075076 @default.
• W2896588461 cites W1981905971 @default.
• W2896588461 cites W1984747135 @default.
• W2896588461 cites W2005842510 @default.
• W2896588461 cites W2009527110 @default.
• W2896588461 cites W2012403735 @default.
• W2896588461 cites W2044564816 @default.
• W2896588461 cites W2051021899 @default.
• W2896588461 cites W2071364157 @default.
• W2896588461 cites W2082176290 @default.
• W2896588461 cites W2098354451 @default.
• W2896588461 cites W2101859975 @default.
• W2896588461 cites W2107814019 @default.
• W2896588461 cites W2115646671 @default.
• W2896588461 cites W2121902152 @default.
• W2896588461 cites W2159746573 @default.
• W2896588461 cites W2171512205 @default.
• W2896588461 cites W2214021454 @default.
• W2896588461 cites W2513988219 @default.
• W2896588461 cites W2610797655 @default.
• W2896588461 cites W2621684067 @default.
• W2896588461 doi "https://doi.org/10.1177/1533033818806318" @default.
• W2896588461 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6195005" @default.
• W2896588461 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30317929" @default.
• W2896588461 hasPublicationYear "2018" @default.
• W2896588461 type Work @default.
• W2896588461 sameAs 2896588461 @default.
• W2896588461 citedByCount "9" @default.
• W2896588461 countsByYear W28965884612019 @default.
• W2896588461 countsByYear W28965884612020 @default.
• W2896588461 countsByYear W28965884612022 @default.
• W2896588461 countsByYear W28965884612023 @default.
• W2896588461 crossrefType "journal-article" @default.
• W2896588461 hasAuthorship W2896588461A5030364395 @default.
• W2896588461 hasAuthorship W2896588461A5036351853 @default.
• W2896588461 hasAuthorship W2896588461A5037020713 @default.
• W2896588461 hasAuthorship W2896588461A5049066873 @default.
• W2896588461 hasAuthorship W2896588461A5064981458 @default.
• W2896588461 hasAuthorship W2896588461A5066700160 @default.
• W2896588461 hasAuthorship W2896588461A5074236699 @default.
• W2896588461 hasAuthorship W2896588461A5081787271 @default.
• W2896588461 hasAuthorship W2896588461A5084272595 @default.
• W2896588461 hasBestOaLocation W28965884611 @default.
• W2896588461 hasConcept C126322002 @default.
• W2896588461 hasConcept C126838900 @default.
• W2896588461 hasConcept C141071460 @default.
• W2896588461 hasConcept C155806632 @default.
• W2896588461 hasConcept C197934379 @default.
• W2896588461 hasConcept C2776256026 @default.
• W2896588461 hasConcept C2778120868 @default.
• W2896588461 hasConcept C2780387249 @default.
• W2896588461 hasConcept C2781413609 @default.
• W2896588461 hasConcept C2989005 @default.
• W2896588461 hasConcept C44249647 @default.
• W2896588461 hasConcept C509974204 @default.
• W2896588461 hasConcept C71924100 @default.
• W2896588461 hasConceptScore W2896588461C126322002 @default.
• W2896588461 hasConceptScore W2896588461C126838900 @default.
• W2896588461 hasConceptScore W2896588461C141071460 @default.
• W2896588461 hasConceptScore W2896588461C155806632 @default.
• W2896588461 hasConceptScore W2896588461C197934379 @default.
• W2896588461 hasConceptScore W2896588461C2776256026 @default.
• W2896588461 hasConceptScore W2896588461C2778120868 @default.
• W2896588461 hasConceptScore W2896588461C2780387249 @default.
• W2896588461 hasConceptScore W2896588461C2781413609 @default.
• W2896588461 hasConceptScore W2896588461C2989005 @default.
• W2896588461 hasConceptScore W2896588461C44249647 @default.
• W2896588461 hasConceptScore W2896588461C509974204 @default.
• W2896588461 hasConceptScore W2896588461C71924100 @default.
• W2896588461 hasLocation W28965884611 @default.
• W2896588461 hasLocation W28965884612 @default.
• W2896588461 hasLocation W28965884613 @default.
• W2896588461 hasLocation W28965884614 @default.
• W2896588461 hasOpenAccess W2896588461 @default.
• W2896588461 hasPrimaryLocation W28965884611 @default.
• W2896588461 hasRelatedWork W1963579780 @default.
• W2896588461 hasRelatedWork W1983863207 @default.
• W2896588461 hasRelatedWork W2074010027 @default.
• W2896588461 hasRelatedWork W2089310292 @default.
• W2896588461 hasRelatedWork W2093044092 @default.
• W2896588461 hasRelatedWork W2292349525 @default.
• W2896588461 hasRelatedWork W3031853862 @default.
• W2896588461 hasRelatedWork W3086650356 @default.
• W2896588461 hasRelatedWork W3214062064 @default.

• next